Skip to main content

2020

October 28, 2020
Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffectiveness.…
October 28, 2020
Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluating…
October 26, 2020
Objective: A pooled analysis evaluated reductions in migraine and headache days among chronic migraine (CM) patients with comorbid depression (scores ≥10 on the 9-item Patient Health Questionnaire […
October 26, 2020
Introduction: Previous studies have documented increased risk of motor vehicle accidents (MVAs) in patients with obstructive sleep apnea (OSA); however, clinical practices for diagnosing/treating OSA…
October 22, 2020
Background: Treatment-resistant depression (TRD) is a relatively common occurrence in clinical practice, with up to 50% to 60% of patients not achieving adequate response following antidepressant…
October 20, 2020
BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe…
October 20, 2020
Background: The benefits of telehealth from a social, financial, and practical sense are well established. However, there are many gaps in the literature regarding telemedicine services in vulnerable…
October 19, 2020
Background: The Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1-7) is usually the primary efficacy measure in tardive dyskinesia (TD) clinical trials. However, item 8 of the…
October 19, 2020
Introduction: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotic medications that jeopardizes adherence to…
Back to Top